Patents by Inventor Hirotada Fujita
Hirotada Fujita has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11260124Abstract: To provide a superior anti-human NGF antibody Fab fragment that maintains a high neutralizing activity, and that reduces systemic side-effects arising from systemic exposure while expressing a local drug effect, and means for treating postoperative pain by using such antibody fragment. An anti-human NGF antibody Fab fragment comprising a heavy-chain fragment consisting of the amino acid sequence shown by SEQ ID NO:5 and a light-chain consisting of the amino acid sequence shown by SEQ ID NO: 8.Type: GrantFiled: May 20, 2016Date of Patent: March 1, 2022Assignee: Astellas Pharma Inc.Inventors: Hirotsugu Tanaka, Hirotada Fujita, Toshiaki Aoki
-
Publication number: 20180147281Abstract: To provide a superior anti-human NGF antibody Fab fragment that maintains a high neutralizing activity, and that reduces systemic side-effects arising from systemic exposure while expressing a local drug effect, and means for treating postoperative pain by using such antibody fragment. An anti-human NGF antibody Fab fragment comprising a heavy-chain fragment consisting of the amino acid sequence shown by SEQ ID NO:5 and a light-chain consisting of the amino acid sequence shown by SEQ ID NO: 8.Type: ApplicationFiled: May 20, 2016Publication date: May 31, 2018Applicant: Astellas Pharma Inc.Inventors: Hirotsugu TANAKA, Hirotada FUJITA, Toshiaki AOKI
-
Patent number: 8715655Abstract: The present invention provides a human anti-?9 integrin antibody or an antibody fragment which specifically recognize human ?9 integrin and mouse ?9 integrin, inhibit interaction with their ligands, particularly, the antibody or antibody fragment which recognize loop regions of human and mouse ?9 integrins, a gene encoding the antibody or antibody fragment, a recombinant expression vector containing the gene, a transformant harboring the gene, production method of human anti-?9 integrin antibody or antibody fragment using the transformant, and an agent for the prophylaxis or treatment of rheumatoid arthritis which contains the antibody or antibody fragment.Type: GrantFiled: December 26, 2008Date of Patent: May 6, 2014Assignee: Juridical Foundation The Chemo-Sero-Therapeutic Research InstituteInventors: Masaharu Torikai, Daisuke Ishikawa, Toshihiro Nakashima, Hirofumi Higuchi, Fumihiko Sakai, Nobuchika Yamamoto, Hirotada Fujita, Katsunari Taguchi
-
Patent number: 8603476Abstract: The present invention provides a humanized anti-human ?9 integrin antibody having improved activity and/or property as compared to a donor mouse anti-human ?9 integrin antibody, namely, a humanized anti-human ?9 integrin antibody containing a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:11 and a light-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:17, a humanized anti-human ?9 integrin antibody containing a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:13 and a light-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:17, a humanized anti-human ?9 integrin antibody containing a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:15 and a light-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:9, and a means for the prophylaxis or treatment of various diseases involving human ?9 integrin in the pathogenesis, whichType: GrantFiled: January 9, 2009Date of Patent: December 10, 2013Assignee: Astellas Pharma Inc.Inventors: Kenji Uehara, Hirofumi Higuchi, Toshihiro Nakashima, Daisuke Ishikawa, Nobuchika Yamamoto, Hirotada Fujita, Fumihiko Sakai
-
Publication number: 20110059077Abstract: The present invention provides a humanized anti-human ?9 integrin antibody having improved activity and/or property as compared to a donor mouse anti-human ?9 integrin antibody, namely, a humanized anti-human ?9 integrin antibody containing a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:11 and a light-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:17, a humanized anti-human ?9 integrin antibody containing a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:13 and a light-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:17, a humanized anti-human ?9 integrin antibody containing a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:15 and a light-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:9, and a means for the prophylaxis or treatment of various diseases involving human ?9 integrin in the pathogenesis, whichType: ApplicationFiled: January 9, 2009Publication date: March 10, 2011Applicants: JURIDICAL FDN THE CHEMO-SERO-THERAPEUTIC RES INST., ASTELLAS PHARMA INC.Inventors: Kenji Uehara, Hirofumi Higuchi, Toshihiro Nakashima, Daisuke Ishikawa, Nobuchika Yamamoto, Hirotada Fujita, Fumihiko Sakai
-
Publication number: 20110014193Abstract: The present invention provides a humanized anti-human ?9 integrin antibody having improved activity and/or property as compared to donor mouse anti-human ?9 integrin antibody, namely, a humanized anti-human ?9 integrin antibody comprising a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO: 1 or the amino acid sequence shown by SEQ ID NO: 1 wherein one or several amino acids are substituted, deleted, inserted and/or added and a light-chain variable region consisting of the amino acid sequence shown by SEQ ID NO: 61 or the amino acid sequence shown by SEQ ID NO: 61 wherein one or several amino acids are substituted, deleted, inserted and/or added, as well as a means for preventing or treating various diseases involving human ?9 integrin in their pathogenesis, which uses the antibody.Type: ApplicationFiled: July 9, 2009Publication date: January 20, 2011Applicant: JURIDICAL FDN THE CHEMO-SERO-THERAPEUTIC RES INSTInventors: Kenji Uehara, Hirofumi Higuchi, Toshihiro Nakashima, Daisuke Ishikawa, Nobuchika Yamamoto, Hirotada Fujita, Fumihiko Sakai
-
Publication number: 20110014213Abstract: The present invention provides a human anti-?9 integrin antibody or an antibody fragment which specifically recognize human ?9 integrin and mouse ?9 integrin, inhibit interaction with their ligands, particularly, the antibody or antibody fragment which recognize loop regions of human and mouse ?9 integrins, a gene encoding the antibody or antibody fragment, a recombinant expression vector containing the gene, a transformant harboring the gene, production method of human anti-?9 integrin antibody or antibody fragment using the transformant, and an agent for the prophylaxis or treatment of rheumatoid arthritis which contains the antibody or antibody fragment.Type: ApplicationFiled: December 26, 2008Publication date: January 20, 2011Applicant: Juridical Fdn. The Chemo-Sero-Therap. Res. Ins.Inventors: Masaharu Torikai, Daisuke Ishikawa, Toshihiro Nakashima, Hirofumi Higuchi, Fumihiko Sakai, Nobuchika Yamamoto, Hirotada Fujita, Katsunari Taguchi